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Abstract
Trask/CDCP1 is a transmembrane protein with a large extracellular and small intracellular domains. The intracellular domain
(ICD) undergoes tyrosine phosphorylation by Src kinases during anchorage loss and, when phosphorylated, Trask functions
to inhibit cell adhesion. The extracellular domain (ECD) undergoes proteolytic cleavage by serine proteases, although the
functional significance of this remains unknown. There is conflicting evidence regarding whether it functions to signal the
phosphorylation of the ICD. To better define the structural determinants that mediate the anti-adhesive functions of Trask,
we generated a series of deletion mutants of Trask and expressed them in tet-inducible cell models to define the structural
elements involved in cell adhesion signaling. We find that the ECD is dispensable for the phosphorylation of the ICD or for
the inhibition of cell adhesion. The anti-adhesive functions of Trask are entirely embodied within its ICD and are specifically
due to tyrosine phosphorylation of the ICD as this function is completely lost in a phosphorylation-defective tyrosine-
phenylalanine mutant. Both full length and cleaved ECDs are fully capable of phosphorylation and undergo
phosphorylation during anchorage loss and cleavage is not an upstream signal for ICD phosphorylation. These data
establish that the anti-adhesive functions of Trask are mediated entirely through its tyrosine phosphorylation. It remains to
be defined what role, if any, the Trask ECD plays in its adhesion functions.
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Introduction
Cell adhesion to the extracellular matrix (ECM) is an important
function in metazoans. Adhesion to matrix forms structural
anchorage points that function to map the architectural layout
of cells within a tissue framework, while linking the intracellular
actin cytoskeleton with the extracellular matrix (ECM), providing
structural stability at the tissue level. Cell adhesion also mediates
intracellular signaling functions that regulate aspects of cell
behavior cell growth, survival, proliferation, and migration. The
regulation of cell adhesion is a highly coordinated process
involving heterodimeric integrin receptors and many other classes
of cytoplasmic and membrane proteins. Upon integrin engage-
ment to the ECM and clustering of integrins at sites of cell
adhesion to matrix, macromolecular complexes are assembled in
association with the intracellular tails of activated integrins [1,2,3].
Within these focal adhesions, focal adhesion kinase (FAK) is
activated by autophosphorylation at tyrosine 397, creating a
binding site for the Src SH2 domain [1,4]. Upon binding to FAK,
Src is activated and phosphorylates a number of additional
tyrosine residues on FAK, creating additional binding sites for
SFKs and other proteins. Activated Src also phosphorylates a
number of additional cytoskeletal proteins including paxillin and
p130Cas and proteins involved in regulating the RhoA, Rac1, and
Cdc42 GTPases [5]. These events function to stabilize focal
adhesions, generating a force-induced mechanical link with the
actin cytoskeleton, and regulate the surrounding membrane
dynamics. While our understanding of adhesion complex
formation has greatly evolved in recent years, our understanding
of how adhesion complexes are disrupted remains largely
primitive. The mechanisms that promote the disruption of cell
adhesion are of particular interest in cancer biology, specially for
the study of invasion and metastasis. We have been studying a cell
surface protein that is a negative regulator of cell adhesion.
Trask (Transmembrane and Associated with Src Kinases) is a
membrane glycoprotein whose functions are not yet well
understood. Trask (aka CDCP1, SIMA135, gp140) has been
independently identified by several groups pursuing different lines
of study. One group identified it as a transcript expressed in colon
cancers [6]; our group identified it as a Src substrate phosphor-
ylated during mitotic detachment [7]; another group identified it
as an adhesion related protein tyrosine phosphorylated following
exposure to suramin or vanadate [8], and another group identified
it in a search for surface antigens associated with a more metastatic
cancer phenotype [9]. Trask/CDCP1 is a 140 kD transmembrane
glycoprotein with a large extracellular domain (ECD) containing
CUB domains, and a smaller intracellular domain (ICD)
containing five tyrosines [7,10]. The tyrosine phosphorylation of
Trask is tightly regulated and reciprocally linked with the state of
cell adhesion. The tyrosine phosphorylation of Trask in cultured
cells occurs when cells are induced to detach by trypsin or EDTA,
or seen spontaneously during mitotic detachment [7,10] [8]. In
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leads to the loss of cell adhesion and a detached phenotype [7].
Trask is widely expressed in human epithelial tissues, but its
phosphorylation is only seen in mitotically detached or shedding
cells, consistent with its role in the negative regulation of cell
adhesion [10]. The phosphorylation of Trask is seen in many
cancers, including some pre-invasive cancers as well as in invasive
tumors and in tumor metastases [11]. The functional implications
of Trask phosphorylation in tumors is currently unknown.
Since Trask has little homology with other genes or gene
families, its functions have been difficult to predict and much more
experimental evidence from biochemical and biological studies are
necessary to begin to understand its functions. Several studies
mentioned previously point to a role in the regulation of cell
adhesion. But it remains unclear whether this adhesion function is
mediated through tyrosine phosphorylation or through the
functions of the extracellular domain, or a more complex
outside-in or inside-out signaling function involving both the
intracellular and extracellular domains. The functions of the Trask
ECD are largely unknown. CUB domains are extracellular
protein-protein interaction modules, typically found in many
proteases. Indeed Trask is stably associated with the CUB domain
containing membrane protease MT-SP1 and is a proteolytic
substrate of MT-SP1 [7]. Trask is cleaved by other serine
proteases including trypsin and plasmin as well and this accounts
for the expression of larger (140 kD) and smaller (approximately
80 kD) forms of Trask that are typically observed in different ratios
in different cell types [11,12].
Some investigators have suggested that cleavage of the Trask/
CDCP1 ECD results in phosphorylation of its ICD [12]. The
evidence that has promoted this suggestion is that cells treated with
trypsin simultaneously undergo Trask cleavage, cell detachment,
and Trask phosphorylation [8,10,12]. Although the cleavage and
phosphorylation of Trask/CDCP1 may occur simultaneously in
some circumstances, the cleavage of the ECD does not appear to
be required for phosphorylation of the ICD as the phosphorylation
of Trask is also seen with EDTA-induced cell detachment without
any increase in Trask cleavage beyond the basal state [11].
Clearly, we need more experimental studies to explore the
functional relationship between the Trask ECD and ICD,
particularly as it pertains to its role in the regulation of cell
adhesion. In the current study we have undertaken a structure-
function analysis of Trask in order to determine whether its anti-
adhesive functions reside within the ECD or ICD and whether this
involves transmembrane signaling. The data reveals that the anti-
adhesive functions of Trask are directly mediated through the
tyrosine phosphorylation of its ICD and the ECD is dispensible for
its tyrosine phosphorylation or for the inhibition of cell adhesion
when phosphorylated.
Results
We previously established MDA-468 cells with tet-inducible
overexpression of Trask and found that overexpression of Trask is
associated with the loss of cell adhesion and continued growth in a
rounded suspended state [7]. To determine the structural features
of Trask that are required for this anti-adhesive function, we
generated a series of Trask deletion mutants that lack residues
within the ICD or ECD. The structure of these mutants, the
specific regions deleted, and the c-terminal myc tag are depicted
schematically in Figure 1. Each of these constructs were stably
transfected into MDA-468 cells previously established to express
the tet repressor (MDA-468TR). For each Trask mutant, multiple
clones were expanded and analyzed and the dox-inducible
expression of the Trask mutants confirmed by anti-myc immuno-
blotting (Figure 2A). The M5 and M9 mutants retain the entire
ECD, while the M4, M7, and M8 mutants have deletions of nearly
the entire ECD. The M5 and M9 mutants are expressed as both
larger and smaller forms consistent with the partial proteolytic
cleavage of their ECDs, as occurs with the wildtype Trask. The
functions of the intracellular domain are not required for the
Figure 1. Generation of Trask mutant constructs. Schematic representation of the Trask mutant constructs. All constructs contain the signal
peptide and transmembrane regions for proper membrane localization and an in-frame c-terminal myc tag for easy identification. The triangles
indicate the naturally occurring cleavage sites after the signal peptide and at Arg368 of the extracellular domain. Abbreviations indicate the signal
peptide (SP), CUB domains, transmembrane region (TM), proline-rich region (PRR), and myc tags. The extracellular region homology to CUB domains
is low, and the precise region and number of CUB domains is somewhat speculative. The location of the 5 intracellular tyrosines are indicated by Y.
doi:10.1371/journal.pone.0019154.g001
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undergoes proteolytic cleavage. The partial nature of the
proteolytic cleavage is similar to that seen with tet-inducible
overexpression of the wildtype Trask which we have previously
shown [7]. While there are differences in the relative expression of
cleaved and uncleaved products of the wildtype and mutant Trask
constructs, these could be due to the different stability of these
proteins.
All constructs localize to the cell membrane as shown by
fluorescence microscopy of anti-myc immunostained cells follow-
ing doxycycline treatment (Figure 2B). Therefore neither the ECD
or the ICD functions are required for membrane localization. The
YDF mutant also localizes to the membrane indicating that
phosphorylation is also not required for membrane localization.
The signal peptide and transmembrane regions were preserved in
all constructs, since they are known to be required for proper
membrane localization of type I transmembrane proteins.
The state of phosphorylation of each expressed construct was
determined by anti-myc immunoprecipitation followed by phos-
photyrosine immunoblotting. When overexpressed, wildtype Trask
undergoes constitutive tyrosine phosphorylation (Figure 3A). The
reasons for this are not clear, but are likely due to the saturation of
dephosphorylation mechanisms. The M4, M5, and M8 constructs
that contain ICD regions also undergo tyrosine phosphorylation
(Figure 3A). The M8 mutant, which retains only 3 of the 5
intracellular tyrosines, also undergoes tyrosine phosphorylation.
There is no detectable tyrosine phosphorylation of the M7 mutant
which lacks an intracellular domain (Figure S1) or the YDF mutant
which lacks critical tyrosines within the ICD (Figure 3A).
We previously described that Trask is physically associated with
Src kinases, in particular with Yes [7]. The presence of this
interaction was determined for all the Trask mutants. The M4,
M5, and M8 constructs that contain ICD regions and phosphor-
ylated tyrosines interact with Yes (Figure 3B). The mutants that
lack the ICD or the three intracellular tyrosines fail to interact with
Yes (Figure 3B). The YDF mutant also fails to interact with Yes
(Figure 3C). Conclusions cannot be drawn regarding any
quantitative differences among the mutants with regards to
tyrosine phosphorylation or with regards to interaction with Yes.
This is because the constructs have different expression charac-
teristics, likely due to different protein half lives, precluding direct
comparative analyses of their phosphorylation or interaction
levels.
Next we determined the effect of each of the Trask mutants on
the anti-adhesive function of Trask. When overexpressed, Trask is
constitutively phosphorylated (shown above) and inhibits cell
spreading and adhesion [7]. The effects on cell adhesion were
qualitatively and quantitatively assessed following doxycycline
induction. The M4, M5, and M8 mutant constructs retain the
ability to inhibit cell adhesion similar to wild type Trask
(Figure 4A,B). After doxycycline induction, these cells have 10%
(wt), 9% (M4), 9%(M5), and 28%(M8) of the number of adherent
cells seen in their uninduced controls. On the other hand the M7,
M9, and YDF mutants fail to inhibit cell adhesion showing cell
adhesion after doxycycline induction that is 96% (M7), 113%
(M9), and 123% (YDF) of their uninduced controls. These results
are consistent among four different clones of each transfectant and
therefore are not due to clonal variation. Data obtained from
additional clones, with microscopic images from several additional
fields and magnifications, and quantitative adhesion assays from
additional clones are shown in Figure S2. When doxycycline
induction is initiated in detached cells at the time of plating, cells
fail to adhere. When the induction is initiated in fully adherent
cells, there is also an inhibition of cell adhesion, although the loss
of cell adhesion occurs more gradually. The induction of Trask
overexpression results in the dephosphorylation of focal adhesion
kinase, consistent with the disruption of cell adhesion and
dismantling of focal adhesions (Figures 4C and S3). This is seen
with the wildtype Trask as well as with the M4, M5 and M8
mutants. The M7 and M9 mutants that lack the ICD fail to inhibit
cell adhesion. The YDF mutant also fails to inhibit cell adhesion or
inhibit focal adhesion signaling.
Figure 2. Inducible expression of Trask mutants in MDA-468 cells. A) MDA-468TR cells were engineered to inducibly overexpress the M4,
M5, M7, M8, and M9 and YDF Trask mutants in response to doxycycline treatment. For each construct four clones were studied to account for clonal
variability. The dox-inducible expression of the M4, M5, M7, M8, and M9 and YDF Trask mutants are shown by anti-myc immunoblots. The myc
immunoblots for the wt-Trask over-expressing cells were previously published [7]. These induction blots are representative of two experiments done
with the entire clone set, and with 4 experiments done with selected Trask-M4 and Trask-YDF clones. B) The membrane localization of each of the
induced constructs was verified following doxycycline induction by anti-myc staining of fixed cells and immunofluorescence microscopy.
doi:10.1371/journal.pone.0019154.g002
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embodied within the ICD and are entirely dependent on the
tyrosine phosphorylation of the ICD. The ECD appears to be
dispensible for this function as shown by mutants that lack the
ECD. It remains possible that the mutants lacking the ECD inhibit
adhesion through a dominant negative mechanism involving the
endogenous full length Trask and its ECD. To rule out this
possibility we established HEK293 cells with tet-inducible
expression of the M4 Trask mutant (Figure 5A). HEK293 cells
have no detectable endogenous expression of Trask, enabling us to
test the anti-adhesive functions of the Trask ICD directly and
definitively, ruling out a potential orthogonal role for the
endogenous Trask ECD. Expression of the Trask M4 mutant in
these cells leads to a profound inhibition of cell adhesion
(Figure 5B). This confirms that the anti-adhesive functions of
Trask are contained entirely within its ICD.
Although the ECD is not required for the anti-adhesive
functions of Trask, it may still provide an outside-in signal to
induce the phosphorylation of Trask, or it may function to inhibit
Trask phosphorylation until it is cleaved, and thereby function
indirectly in the regulation of the anti-adhesive functions of Trask.
To interrogate this, we generated a mutant Trask construct that is
resistant to cleavage. We have previously identified the site of
cleavage by MT-SP1 in MDA-468 cells as arginine 368 [7]. To
generate an MT-SP1 resistant construct we mutated this critical
arginine to aspartate. The R368D Trask mutant (named M10) was
confirmed to be resistant to cleavage in transient transfection
assays. We also generated a Trask mutant that is identical to the
membrane-bound proteolytic product of Trask cleavage at R368
(named M11). When expressed in MDA-468 cells or in HEK293
cells, both the cleavage-resistant M10 mutant and the cleavage-
product M11 mutant undergo tyrosine phosphorylation very
Figure 3. Signaling properties of Trask mutants. A) The induced constructs were immunoprecipitated by anti-myc antibodies from the
engineered transfectants cell types and vector control cells and immunoblotted with pTyr antibodies. The lysates from the larger size constructs (wt,
YDF, M5) were run on lower % gels and the smaller size constructs (M4, M8) were run on higher % gels for optimal separation and identification. The
bands corresponding to the various constructs are indicated by arrows. The starts indicate the immunoglobulin chains. These blots are representative
of multiple experiments (4X for wt, 4X for YDF, 2X for M5, 2X for M4, 3X for M8, and 2X for vector control). B) Anti-yes immune complexes were
obtained from each of the mutant cell types and immunoblotted using anti-myc antibodies to detect the co-immunoprecipitation of the transfected
constructs. The M8 mutant Trask protein appears as 3 bands likely due to the significant effect of differential phosphorylation on the gel migration of
this small construct. These blots are representative of multiple experiments (5X for wt, 1X for M5, 2X for M7, 2X for M4, and 3X for M8). C) The
interaction of the YDF mutant with Yes was similarly assayed as above. The anti-myc immunoblot shows that the Yes-Trask interaction is lost in the
YDF mutant. The immunoblots were redone using anti-Trask antibodies, again confirming that the Yes-Trask interaction is lost in the YDF mutant. The
stars indicates the immunoglobulin chains. The arrows indicate the Yes protein. These blots are representative of three experiments.
doi:10.1371/journal.pone.0019154.g003
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ml doxycycline and the following day imaged under phase contrast microscopy. These views are representative of multiple fields of view (shown in
Figure S2) and representative of multiple independent experiments (.10X for wt, 5X for M4, 3X for M5, 3X for M7, 3X for M8, 3X for M9, and 5X for
YDF). B) The indicated cell types were treated with 1 ug/ml doxycycline or control and the following day seeded into 96-well plates in triplicate wells
and the adherent cell population was quantified by crystal violet staining as described in methods. Results were normalized to non-induced controls,
and averaged across the triplicate wells as well as across three independent experiments done on different days (n=9), in different clones, with the
indicated SEM. The reduced cell adhesion following dox induction is statistically significant for WT-Trask (p,0.0001), M4-Trask (p,0.0001), M5-Trask
(p,0.0001), and M8-Trask (p,0.0001) cell types. C) The indicated cell types were treated with 1 ug/ml doxycycline or control overnight and the
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also be cleaved at sites other than R368 [12], this does not impact
the interpretation of our experiment, since the M10 (R368D)
mutant is clearly fully resistant to cleavage in our experiments. The
cleavage-product M11 mutant appears more abundantly phos-
phorylated than wildtype or M10 Trask. Trask cleavage is clearly
not required for its phosphorylation since the uncleaved wildtype
Trask and the cleavage-resistant M10 Trask mutant readily
undergo tyrosine phosphorylation. The absence of a relationship
between Trask cleavage and its phosphorylation is easily evident
when comparing cell lines. There are cell types in which Trask is
predominantly uncleaved, and wherein Trask undergoes detach-
ment-induced phosphorylation without any cleavage (Figure 5C).
There are also cell lines wherein Trask is expressed as a blend of
cleaved and uncleaved forms, and both forms undergo detach-
ment-induced phosphorylation (Figure 5C). There are also cell
types wherein Trask is predominantly cleaved wherein it is this
form that undergoes detachment-induced phosphorylation
(Figure 5C). Therefore, the phosphorylation of Trask is tightly
regulated by cell anchorage as we have previously described [10].
The proteolytic cleavage of Trask does not appear to be a
significant regulator of its phosphorylation. The mechanisms that
regulate and determine the extent of cleavage of Trask are
currently unknown.
Figure 5. Effects of Trask phosphorylation in HEK293 cells. A) HEK293TR cells were engineered to express the M4-Trask mutant in a tet-
inducible fashion. The doxycycline inducible expression of M4-Trask is shown here for four different clones. This blot is representative of two
independent experiments. B) HEK293TR/M4-Trask cells were plated in the presence or absence of 1 ug/ml doxycycline and the following day
observed under phase contrast microscopy. Although not obvious in these still photographs, many of the cell clumps in the doxycycline treated arm
are loosely adhered or entirely in suspension. This experiment has been performed 4 times with similar results.
doi:10.1371/journal.pone.0019154.g005
following day total cell lysates were used to determine focal adhesion signaling. FAK phosphorylation was done by anti-FAK immunoprecipitation
followed by anti-phosphotyrosine immunoblotting. These blots are representative of multiple experiments (5X for wt, 5X for vector control, 2X for
M4, 2X for M5, 2X for M7, 2X for M8, 2X for M9, and 5X for YDF).
doi:10.1371/journal.pone.0019154.g004
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Trask/CDCP1 is a transmembrane protein whose functions are
not yet well understood. It has been identified in several
independent lines of research as a cancer-associated protein and
proposed to have functions relevant to tumor progression. But the
data sets that have emerged in the investigation of its role in cancer
progression have been mixed and partly conflicting. Some studies,
mostly looking at Trask RNA expression, have suggested that its
expression is significantly increased in cancers Scherl-Mostageer,
2001 #90; Miyazawa, 2010 #238; Perry, 2007 #82; Uekita, 2008
#78}. A limited number of studies appear to suggest a function in
cancer invasion or metastasis [9,13]. But in larger immuno-
histochemical studies it has become clear that Trask is widely
expressed in most normal epithelial tissues, quite abundantly in
some, and similarly widely expressed in epithelial cancers without
significant evidence of overexpression [10,11]. There is immuno-
histochemical evidence showing reduced Trask/CDCP1 expres-
sion in some cancers and biochemical data showing that a
reduction or loss of expression in some cancer cells due to
promoter hypermethylation [14,15]. Attempts to correlate the
level of expression of Trask in human tumors with clinical
outcome has also produced conflicting data sets as both poorer
and better prognoses have been linked with higher Trask
expression [16,17,18].
Clearly our understanding of Trask function is still evolving, and
awaits more insight into its biochemical and cellular functions.
One function that is clear is a function in the regulation of cell
adhesion. In normal cells, the phosphorylation of Trask is
exclusively seen in the unanchored state and its overexpression
inhibits cell adhesion [7,8,10]. Some have suggested that
phosphorylation of Trask is induced by the proteolytic cleavage
of its ECD [8,12]. This would suggest an outside-in signaling
function. To more directly investigate what functions of Trask
mediate its anti-adhesive effects, we conducted a structure-
function analysis of Trask using a series of mutant constructs.
This analysis reveals that the anti-adhesive functions of Trask are
specfically due to its tyrosine phosphorylation. Its ECD is
dispensible for the inhibition of cell adhesion as mutant constructs
lacking the ECD are fully capable of inhibiting cell adhesion. The
ECD also does not indirectly regulate cell adhesion through the
regulation of Trask phosphorylation since both the wildtype full
length Trask or a cleavage-resistant Trask full length Trask mutant
efficiently undergo tyrosine phosphorylation. Since we find higher
phosphorylation of cleaved Trask in MDA-468 cells, it remains
possible that cleaved Trask is more efficient as a substrate for
phosphorylation. Therefore the proteolytic cleavage of Trask may
provide one input that influences its phosphorylation state, but this
is a quantitative difference and may have contextual relationships
that we don’t yet understand. The mechanisms that regulate the
proteolytic cleavage of Trask are not currently understood. As
such the basis for the varying degrees of Trask cleavage seen
among different cell lines remains to be explained. Even the same
cell line shows modest changes in the degree of Trask cleavage in
different experiments without a methodological basis or an
obvious phenotypic difference.
These studies establish that the anti-adhesive functions of Trask
are specifically due to the tyrosine phosphorylation of its ICD.
Therefore the functions of the Trask ECD remain largely
unknown at this time, awaiting hypotheses regarding what its
functions may be, and studies designed to specifically test such
hypotheses.
Materials and Methods
Cell culture and reagents
MDA-468 and HEK293 cells were obtained from the American
Type Culture Collection and grown in DMEM media supple-
mented with 10% heat-inactivated tetracycline-free fetal bovine
serum, and 100 U/ml penicillin, 100 mg/ml streptomycin, 4 mM
glutamine, and incubated at 37 C in 5% CO2. To force cells into
suspension, cells were washed in PBS and exposed to a 2 mM
solution of EDTA in Hank’s buffer, and when fully detached, were
cultured in growth media in ULC plates (Corning) for 2 hours.
Figure 6. Trask cleavage and phosphorylation. A,B) HEK293 (A)
or MDA-468 (B) cells were transiently transfected with the indicated
mutant constructs or wildtype or vector controls and total cell lysates
were assayed as indicated. These blots are representative of multiple
experiments (shown in Figure S4). C) Cell lysates from five cell lines
were harvested while adherent (A) or after 2 hours of culture in
suspension (S) and immunoblotted as indicated. Lanes correspond to 1)
L3.3 cells, 2) SW480 cells, 3) DLD1 cells, 4) PC3 cells, and 5) MDA-468
cells. Arrows indicate the larger uncleaved and smaller cleaved forms of
Trask. These blots are representative of two experiments. The MDA-468
blot is representative of .5 independent experiments.
doi:10.1371/journal.pone.0019154.g006
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purchased from SantaCruz Biotechnology (anti-myc 9E10, anti-
phosphotyrosine PY99, anti-FAK A-17) and Wako (anti-yes 1B7),
and anti-Trask M19. Total cellular lysates were harvested in
modified RIPA buffer (10 mM Na phosphate (pH 7.2), 150 mM
NaCl, 0.1% SDS, 1% NP40, 1% Na deoxycholate, protease
inhibitors and 1 mM sodium orthovanadate). For western blotting,
50 ug of each lysate was separated by SDS-PAGE, transferred to
membrane, and immunoblotted using appropriate primary and
secondary antibodies and enhanced chemoluminescence visuali-
zation. For immunoprecipitation studies, 300 ug of lysate was
incubated overnight with specific antibodies, immune complexes
collected by protein G-sepharose beads, washed, and the
denatured complexes immunoblotted as above.
Phase contrast microscopy
Phase contrast microscopy was performed using a Nikon TS-
100F inverted microscope equiped with a Nikon D100 digital
camera attached to the photo port. Images were imported into
Photoshop software, converted to gray scale, and gamma adjusted
for optimal representation.
Adhesion assay
Adhesion was quantitatively assessed by a colorimetric assay
using crystal violet (Sigma), a cytochemical stain that binds to
chromatin. Cells were induced for 16 hrs with or without 1 mg/ml
doxycycline and subsequently plated at a density of 5610
5 cells/ml
in a volume of 100 ml per well in 96 well plates. After two hours,
wells were washed three times with PBS to remove unattached
cells. Attached cells were fixed in cold methanol for 15 minutes,
plates were then air dried and stained with 0.1% crystal violet in
PBS for five minutes at room temperature. After removing the
crystal violet solution, the plates were washed extensively, dried,
and the stain released using 2% SDS in PBS. Stain intensity was
quantified by spectrophotometry at 570 nm using a plate reader.
Immunoblotting and immunofluorescent studies
Western analysis and immunoprecipitation were performed
using horseradish perodixase linked secondary reagents and
visualized by enhanced chemoluminescence. For immunolocali-
zation studies cells were grown on fibronectin coated glass cover
slips and fixed in 4% paraformaldehyde., and permeabilized in
0.1% triton-X. Fixed cells were incubated with 1:100 dilution
primary antibody and subsequently with rhodamine conjugated
secondary antibodies and visualized under fluorescent microscopy
at the appropriate excitation wavelengths.
Vector constructs and transfections
The 2.5 kb human Trask cDNA ORF was cloned into the
pcDNA4/TO/MycHis vector (Invitrogen) in-frame with the c-
terminal myc and his tags under control of the CMV promoter
containing tet-operator sequences as previously described [7]. The
deletion mutants were generated using insertional and deletional
PCR cloning techniques using the following primers and
templates: M4 primers (deletion cloning from full length template,
lacks AA 39–618): TTCAGCCTGGACGAGGATGTG and
GCTTTCTCGTGGCAGAGCAATC; M5 primers (insertional
cloning from full length template, lacks AA 754–837):
CGAATTCGTCCCGGAGTCATGGCCG and CAGTCTC-
GAGTGAGCCGCTGGAATCCTGTAG; M7 primers (deletion
cloning from M4 template, lacks AA 39–618, 692–841):
GGGCCCTTCGAACAAAAACTC and CACACAGCAAAT-
GATGAGCCC; M8 primers (deletional cloning from M5
template, lacks AA 39–618 and 754–837): TTCAGCCTGGAC-
GAGGATGTG and GCTTTCTCGTGGCAGAGCAATC; M9
primers (deletional cloning from M5 template, lacks AA 692–841):
GGGCCCTTCGAACAAAAACTC and CACACAGCAAAT-
GATGAGCCC. The YDF Trask mutant was generated from
the wildtype Trask expression plasmid using the Stratagene Quick
Change II site directed mutagenesis kit. Initially the tyrosines at
position 707 was mutated to phenylalanine, and the product was
subsequently used to mutate the tyrosines at positions 734 and 743
in a second site directed mutagenesis step. The M10 mutant was
generated from the wildtype Trask by site directed mutagenesis to
mutate arginine 368 to aspartate. The M11 mutant was generated
by deletional PCR cloning using the primers TTCTGC-
CCCGCGCGGC and AAGTTTGTCCCTGGCTGTTTC-
GTGTGTCTAGAATCTCGGACC and lacks AAs 29–368. All
constructs were fully sequenced and confirmed. To generate stable
tet-inducible transfectants MDA-468TR cells or 293TR cells (both
previously transfected with the pcDNA6/TR vector) were
transfected with the desired constructs or the parent pcDNA4/
TO/MycHis vector using lipofectamine 2000 and stable transfec-
tants selected in Zeocin. Single cell derived clones from each
construct were picked. Individual clones were picked and gene
expression verified by induction with 1 mg/ml doxycycline for
24 hours and anti-myc western blotting.
Supporting Information
Figure S1 Cell lysates from the indicated transfectant
cell types were immunoprecipitated with anti-myc
antibodies and immunoblotted with anti-phosphotyro-
sine antibodies.
(PDF)
Figure S2 On the following pages several different views
are shown for each cell type with/without doxycycline
induction. The high magnification view is shown to best
demonstrate morphologic characteristics while the low magnifica-
tion view is shown to best demonstrate the generality of the
adhesion phenotype across a larger cell population with much less
selectivity due to the wider field of view. The microscopic images
in this figure are from different clones than the ones shown in the
main paper. This is to show consistency and account for effects
related to clonal variability.
(PDF)
Figure S3 The FAK phosphorylation data of Figure 4C
was quantified by densitometry using the ImageJ
program. The analysis was done separately for each paired data
set (+/2 doxycycline) corresponding to the different transfected
cell types and normalized with respect to the uninduced (-dox)
state. The data was not normalized with respect to total FAK
expression, as a direct effect of the induction on FAK expression
cannot be ruled out.
(PDF)
Figure S4 MDA-468 cells were transiently transfected
with the pcDNA4 vector or vector expressing the wild-
type, M10, or M11 Trask mutants. Cell lysates were assayed
as indicated. These are independent repeats of the experiment
shown in the manuscript.
(PDF)
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